Drug Profile
Research programme: stem cell therapy-sensorineural hearing loss - Inception 3/Roche
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Inception 3; Roche
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sensorineural hearing loss
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Sensorineural hearing loss in Switzerland
- 28 Jul 2018 No recent reports of development identified for research development in Sensorineural hearing loss in USA
- 29 Jul 2016 Early research is ongoing USA and Switzerland